Glioblastoma Vaccine Tumor Therapy Research Progress

Overview

Journal Chin Neurosurg J

Publisher Biomed Central

Specialty Neurology

Date 2022 Jan 20

PMID 35045874

Authors

Tong Zhao

Chunwang Li

Hongliang Ge

Yuanxiang Lin

Dezhi Kang

Affiliations

Soon will be listed here.

Abstract

Glioblastoma (GBM) is the most common primary malignancy of the central nervous system in adults. The prognosis for late-stage glioblastoma (World Health Organization grade IV astrocytic glioma) is very poor. Novel treatment options are sought after and evaluated by clinicians and researchers, and remarkable advances have been made in surgical techniques, radiotherapy, and chemotherapy. However, the treatment of glioblastoma remains extremely difficult and it can extend the lives of patients by only a few months. There has been notable progress in the field of immunotherapy, particularly with the use of tumor vaccines, for treating glioblastoma; especially peptide vaccines and cell-based vaccines such as dendritic cell vaccines and tumor cell vaccines. However, the results of the current clinical trials for vaccination are not satisfactory. This article reviews the progress in the development of vaccines for glioblastoma.

Citing Articles

Ketogenic diet with oxyresveratrol and zinc inhibits glioblastoma and restores memory function and motor coordination.

Gujaran T, Easwaran V, Sankhe R, Bakthavatchalam P, Dsouza H, Pai K Oncol Res. 2025; 33(2):381-395.

PMID: 39866236 PMC: 11753998. DOI: 10.32604/or.2024.049538.

Current Combinatorial Therapeutic Aspects: The Future Prospect for Glioblastoma Treatment.

Gautam M, Gabrani R Curr Med Sci. 2024; 44(6):1175-1184.

PMID: 39695017 DOI: 10.1007/s11596-024-2950-7.

Review of Novel Surgical, Radiation, and Systemic Therapies and Clinical Trials in Glioblastoma.

Valerius A, Webb L, Thomsen A, Lehrer E, Breen W, Campian J Int J Mol Sci. 2024; 25(19).

PMID: 39408897 PMC: 11477105. DOI: 10.3390/ijms251910570.

Immunoediting Dynamics in Glioblastoma: Implications for Immunotherapy Approaches.

Amin T, Hossain A, Jerin N, Mahmud I, Rahman M, Islam S Cancer Control. 2024; 31:10732748241290067.

PMID: 39353594 PMC: 11459535. DOI: 10.1177/10732748241290067.

Pre-Clinical Models for CAR T-Cell Therapy for Glioma.

Vandecandelaere G, Ramapriyan R, Gaffey M, Richardson L, Steuart S, Tazhibi M Cells. 2024; 13(17.

PMID: 39273050 PMC: 11394304. DOI: 10.3390/cells13171480.

References

Strome S, Voss S, Wilcox R, Wakefield T, Tamada K, Flies D . Strategies for antigen loading of dendritic cells to enhance the antitumor immune response. Cancer Res. 2002; 62(6):1884-9. View

Liau L, Prins R, Kiertscher S, Odesa S, Kremen T, Giovannone A . Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res. 2005; 11(15):5515-25. DOI: 10.1158/1078-0432.CCR-05-0464. View

Schumacher T, Bunse L, Pusch S, Sahm F, Wiestler B, Quandt J . A vaccine targeting mutant IDH1 induces antitumour immunity. Nature. 2014; 512(7514):324-7. DOI: 10.1038/nature13387. View

Mildner A, Jung S . Development and function of dendritic cell subsets. Immunity. 2014; 40(5):642-56. DOI: 10.1016/j.immuni.2014.04.016. View

Sampson J, Heimberger A, Archer G, Aldape K, Friedman A, Friedman H . Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010; 28(31):4722-9. PMC: 3020702. DOI: 10.1200/JCO.2010.28.6963. View

Stupp R, Mason W, van den Bent M, Weller M, Fisher B, Taphoorn M . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10):987-96. DOI: 10.1056/NEJMoa043330. View

Curry Jr W, Gorrepati R, Piesche M, Sasada T, Agarwalla P, Jones P . Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma. Clin Cancer Res. 2016; 22(12):2885-96. PMC: 4911283. DOI: 10.1158/1078-0432.CCR-15-2163. View

Dinevska M, Gazibegovic N, Morokoff A, Kaye A, Drummond K, Mantamadiotis T . Inhibition of Radiation and Temozolomide-Induced Glioblastoma Invadopodia Activity Using Ion Channel Drugs. Cancers (Basel). 2020; 12(10). PMC: 7599723. DOI: 10.3390/cancers12102888. View

Palucka K, Banchereau J . Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012; 12(4):265-77. PMC: 3433802. DOI: 10.1038/nrc3258. View

10.

Quail D, Bowman R, Akkari L, Quick M, Schuhmacher A, Huse J . The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas. Science. 2016; 352(6288):aad3018. PMC: 5450629. DOI: 10.1126/science.aad3018. View

11.

Keskin D, Anandappa A, Sun J, Tirosh I, Mathewson N, Li S . Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2018; 565(7738):234-239. PMC: 6546179. DOI: 10.1038/s41586-018-0792-9. View

12.

Steinman R . The dendritic cell system and its role in immunogenicity. Annu Rev Immunol. 1991; 9:271-96. DOI: 10.1146/annurev.iy.09.040191.001415. View

13.

Yao Y, Luo F, Tang C, Chen D, Qin Z, Hua W . Molecular subgroups and B7-H4 expression levels predict responses to dendritic cell vaccines in glioblastoma: an exploratory randomized phase II clinical trial. Cancer Immunol Immunother. 2018; 67(11):1777-1788. PMC: 11028057. DOI: 10.1007/s00262-018-2232-y. View

14.

Nair S, Archer G, Tedder T . Isolation and generation of human dendritic cells. Curr Protoc Immunol. 2012; Chapter 7:7.32.1-7.32.23. PMC: 4559332. DOI: 10.1002/0471142735.im0732s99. View

15.

Schuster J, Lai R, Recht L, Reardon D, Paleologos N, Groves M . A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. Neuro Oncol. 2015; 17(6):854-61. PMC: 4483122. DOI: 10.1093/neuonc/nou348. View

16.

Fecci P, Heimberger A, Sampson J . Immunotherapy for primary brain tumors: no longer a matter of privilege. Clin Cancer Res. 2014; 20(22):5620-9. PMC: 4235630. DOI: 10.1158/1078-0432.CCR-14-0832. View

17.

Polikarpov D, Campbell D, McRobb L, Wu J, Lund M, Lu Y . Near-Infrared Molecular Imaging of Glioblastoma by Miltuximab-IRDye800CW as a Potential Tool for Fluorescence-Guided Surgery. Cancers (Basel). 2020; 12(4). PMC: 7226459. DOI: 10.3390/cancers12040984. View

18.

Heimberger A, Crotty L, Archer G, Hess K, Wikstrand C, Friedman A . Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res. 2003; 9(11):4247-54. View

19.

Bigner D, Pitts O, Wikstrand C . Induction of lethal experimental allergic encephalomyelitis in nonhuman primates and guinea pigs with human glioblastoma multiforme tissue. J Neurosurg. 1981; 55(1):32-42. DOI: 10.3171/jns.1981.55.1.0032. View

20.

Jiang T, Mao Y, Ma W, Mao Q, You Y, Yang X . CGCG clinical practice guidelines for the management of adult diffuse gliomas. Cancer Lett. 2016; 375(2):263-273. DOI: 10.1016/j.canlet.2016.01.024. View